Het eerste schaap(je):
Calypte Biomedical Corporation Receives Large Order for Aware Diagnostic Test from Middle Eastern Distributor
New Sales Initiative Beginning to Yield Results
PORTLAND, Ore.--(BUSINESS WIRE)--
Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that it has received an order for 50,000 tests of its Aware(TM) HIV-1/2 OMT product from LifeLine Scientific, its newly appointed distributor for the UAE and several other countries in the region. The purchase is the first large order resulting from a newly implemented sales initiative.
Donald Taylor, Calypte's President and Chief Executive Officer, stated, "I am delighted to announce that our local office in Dubai has signed such a significant order LifeLine Scientific is affiliated with a leading provider of healthcare in Abu Dhabi and has direct access to an expansive network of hospitals and pharmacies through which it plans to distribute Calypte's oral fluid HIV tests."
Mr. Taylor continued, "This order is the first result of our new sales initiative and reflects the hard work and commitment shown by our people around the world. It also shows the growing market acceptance of our Aware(TM) HIV-1/2 OMT product. While testing with oral fluid is clearly preferred by patients, easier to do, and safer than testing with blood, it has, nonetheless, faced significant adoption hurdles. As this UAE order demonstrates, we are on the right track and beginning to make headway. We are working hard in Africa, the Middle East, India and numerous other countries around the world to close more deals and build on the momentum we are gaining."
Mr. Taylor concluded, "I have been on board for just over three months with a clear mission. This is the firststep in our primary objective to increase sales of our products worldwide. I am looking forward to many others in the months and years to come."
Calypte will begin production as soon as the purchaser's irrevocable letter of credit is approved.
P.